Translational lung cancer research最新文献

{"title":"Optimizing long-term treatment with ALK inhibitors: balancing efficacy and safety.","authors":"Ayuka Dai, Takaaki Sasaki","doi":"10.21037/tlcr-24-671","DOIUrl":"https://doi.org/10.21037/tlcr-24-671","url":null,"abstract":"","PeriodicalId":23271,"journal":{"name":"Translational lung cancer research","volume":"14 3","pages":"657-661"},"PeriodicalIF":4.0,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12000942/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144049668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Single cell RNA-seq and bulk RNA-seq analysis identifies MUC1 as a key gene for lung adenocarcinoma to neuroendocrine transformation.","authors":"Hongxia Li, Tiantian Yang, Yu Chen, Zhiqin Xie","doi":"10.21037/tlcr-24-806","DOIUrl":"https://doi.org/10.21037/tlcr-24-806","url":null,"abstract":"<p><strong>Background: </strong>Tyrosine kinase inhibitors (TKIs) have demonstrated significant effectiveness in treating advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (<i>EGFR</i>) mutations. Despite initial success, resistance to EGFR-TKIs inevitably occurs. One observed phenomenon in resistant lung cancers is the histological transformation from NSCLC to neuroendocrine carcinoma (NEC). The objective of this study is to explore and delineate the genetic and immune features linked to the transition from lung adenocarcinoma (LUAD) to NEC.</p><p><strong>Methods: </strong>Bulk RNA-sequencing and Mendelian randomization (MR) analysis were utilized to identify candidate genes associated with the progression from LUAD to NEC. Expression quantitative trait locus data from publicly available databases were leveraged to pinpoint key genes in relevant tissues. Furthermore, the immune microenvironment was explored using weighted gene co-expression network analysis (WGCNA) and cell-type identification by estimating relative subsets of RNA transcripts (CIBERSORT) databases. Single-cell RNA sequencing data from 16,765 cells across six tissue biopsy samples of LUAD and NEC were scrutinized to investigate cell interaction networks during histological transformation. The molecular pathways involved in dynamic cellular processes were elucidated through the analysis of cellular communication and pseudotime trajectory.</p><p><strong>Results: </strong>Through the use of RNA-sequencing and MR analysis, it was determined that mucin-1 (<i>MUC1</i>) displayed a negative correlation with the progression of LUAD to NEC, as evidenced by its downregulation in clinical specimens. Additionally, MUC1 expression was found to be significantly correlated with the infiltration of diverse immune cell populations, notably CD8⁺ T cells. These results suggest a notable enrichment of neuron-related signaling pathways in the context of transformed NEC. Examination of immune cell infiltration in NEC indicated a reduction in the proportion of CD8⁺ central memory T cells, which has implications for the immune microenvironment and may point to potential therapeutic targets. Further investigation into cell-cell interactions among subpopulations identified the MIF-CD74 axis as the principal signaling pathway facilitating intercellular communication between immune cells and epithelial cells.</p><p><strong>Conclusions: </strong>In conclusion, our study provides insights into the molecular landscape governing the LUAD-to-NEC transition, highlighting <i>MUC1</i> as a potential biomarker. The immune microenvironment is believed to exert a substantial influence on histological transformation, particularly with regards to T cells.</p>","PeriodicalId":23271,"journal":{"name":"Translational lung cancer research","volume":"14 3","pages":"824-841"},"PeriodicalIF":4.0,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12000963/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144028043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting survival in small cell lung cancer patients undergoing various treatments: a machine learning approach.","authors":"Ziran Zhao, Xi Cheng, Yibo Gao, Fengwei Tan, Qi Xue, Shugeng Gao, Jie He","doi":"10.21037/tlcr-24-331","DOIUrl":"https://doi.org/10.21037/tlcr-24-331","url":null,"abstract":"<p><strong>Background: </strong>Small cell lung cancer (SCLC) is highly metastatic, accounting for 1.796 million global cancer-related deaths in 2020, with no established standard care. This study aimed to assess treatment effects on SCLC patient survival across stages and develop a machine learning-based survival prediction tool for accurate overall survival (OS) estimation.</p><p><strong>Methods: </strong>We developed four prediction models: Cox proportional hazard (Cox PH) regression, survival tree (ST), random survival forest (RSF), and gradient boosting survival analysis (GBSA). Patients were randomly split 7:3 into training and test datasets, with 10-fold cross-validation and 50 iterations on the training dataset. Cox PH used hazard ratios, while the other models employed importance values to assess feature predictiveness. Harrell's C-index (C-index) and Brier score (BS) measured model performance, with internal validations using R version 4.2.0.</p><p><strong>Results: </strong>Cox PH outperformed others based on mean C-index and BS. Multivariate analysis across models highlighted distant metastases (M category), tumor stage, and treatment modalities (radiotherapy, chemotherapy, surgery) as key survival predictors. Stratified Cox PH analysis revealed surgery's efficacy in early-stage SCLC (stage II) and radiotherapy's advantage in stage III. Homogeneity was observed in chemotherapy benefits across cancer stages.</p><p><strong>Conclusions: </strong>Surgery, chemotherapy, and radiotherapy are integral in SCLC treatment, contingent on cancer stage and characteristics. Surgery offers promise for early-stage cases, while advanced-stage strategies require further exploration.</p>","PeriodicalId":23271,"journal":{"name":"Translational lung cancer research","volume":"14 3","pages":"736-748"},"PeriodicalIF":4.0,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12000938/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144000454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Palliative surgery is effective in patients with <i>EGFR</i>-mutant lung adenocarcinoma with pleural metastasis.","authors":"Yue Liu, Yifei Zhou, Shuangyi Li, Qianxin Zhou, Jun Li, Nobuhiro Kanaji, Sara Ricciardi, Raja M Flores, Marcello Migliore, Kakeru Hisakane, Yuming Zhu, Wenxin He, Linsong Chen, Dongliang Bian","doi":"10.21037/tlcr-2025-140","DOIUrl":"https://doi.org/10.21037/tlcr-2025-140","url":null,"abstract":"<p><strong>Background: </strong>Pleural metastasis is a common metastatic pattern in patients with epidermal growth factor receptor-mutant lung adenocarcinoma (<i>EGFR</i>-LUADm); however, the value of palliative surgery for these patients remains controversial. The purpose of the present study aims to investigate whether palliative surgery benefits in stage IVA LUADm patients with pleural metastasis, who achieved complete remission of pleural lesions following targeted therapy.</p><p><strong>Methods: </strong>From November 2014 to November 2023, patients with stage IVA <i>EGFR</i>-LUADm with pleural metastasis at Shanghai Pulmonary Hospital were retrospectively included in this study. All the patients received <i>EGFR</i>-tyrosine kinase inhibitor (TKI) monotherapy. The patients were divided into surgical- and non-surgical treatment subgroups. To reduce any selection bias, a 1:2 propensity score matching (PSM) was performed before comparing oncological outcomes between the two groups. The Kaplan-Meier method and log-rank test were used to identify the prognostic factors of these patients.</p><p><strong>Results: </strong>A total of 134 patients who met the inclusion and exclusion criteria were enrolled in this study. Of the 134 patients, 13 received <i>EGFR</i>-TKI monotherapy followed by palliative surgical treatment (the surgical group), and 121 received <i>EGFR</i>-TKI monotherapy alone (the non-surgical group). No significant differences in the baseline characteristics were observed between the subgroups. After PSM, the surgical and non-surgical groups comprised 13 and 26 patients, respectively. The survival analysis showed that the patients in the surgical group had significantly better progression-free survival (PFS) than those in the non-surgical group {surgical <i>vs.</i> non-surgical: median PFS: 43 [95% confidence interval (CI): 30-not available] <i>vs.</i> 11 (95% CI: 10-26, P<0.001)}.</p><p><strong>Conclusions: </strong>Compared with <i>EGFR</i>-TKI monotherapy, palliative surgery combined with <i>EGFR</i>-TKI treatment prolonged the PFS of pleural metastatic <i>EGFR</i>-LUADm patients. A subset of <i>EGFR</i>-LUADm patients with pleural metastasis might be suitable for palliative surgery.</p>","PeriodicalId":23271,"journal":{"name":"Translational lung cancer research","volume":"14 3","pages":"931-939"},"PeriodicalIF":4.0,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12000958/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143996007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A better option for localization of multiple pulmonary nodules in the ipsilateral lung: electromagnetic navigation bronchoscopy-guided preoperative localization.","authors":"Rui Wang, Yongjiang Chen, Chudong Wang, Zijian Li, Yunpeng Zhong, Yunjuan Liang, Shuben Li","doi":"10.21037/tlcr-24-901","DOIUrl":"https://doi.org/10.21037/tlcr-24-901","url":null,"abstract":"<p><strong>Background: </strong>Pulmonary nodules are the most common manifestation of lung cancer. The detection rate of multiple nodules has been increasing and it is essential to figure out a precise way for localization of the nodules. The purpose of this study is to evaluate the efficacy, accuracy and safety of electromagnetic navigation bronchoscopy (ENB)-guided dye marking for localizing multiple ipsilateral nodules compared with computed tomography (CT)-guided lung puncture.</p><p><strong>Methods: </strong>We performed a retrospective cohort study of patients with multiple nodules in the ipsilateral lung who received preoperative localization [including ENB-guided dye marking (ENBDM) or CT-guided lung puncture] and video-assisted thoracoscopic surgery between September 2018 and April 2023. Data were statistically analyzed and visualized using SPSS v25.0 and Microsoft Excel 2019 software.</p><p><strong>Results: </strong>A total of 203 patients were evaluated, among whom 99 underwent ENBDM to localize nodules preoperatively, and 104 were located by CT-guided lung puncture. In terms of localization time, ENB group compared with CT group consumed less time (8.00±4.66 <i>vs.</i> 22.00±8.82 min, P<0.001). In the ENB group, compared with the CT group, there was no radiation exposure. No related complications occurred in the ENB group, including pleural reaction [0 <i>vs.</i> 8 (7.7%), P=0.01], pneumothorax [0 <i>vs.</i> 36 (34.6%), P<0.001], and hemothorax [0 <i>vs.</i> 15 (14.4%), P<0.001]. However, no significant differences were observed in the success localization rate (97.4% <i>vs.</i> 94.9%, P=0.48) between the two groups.</p><p><strong>Conclusions: </strong>For patients with multiple ipsilateral pulmonary nodules, ENBDM can achieve the similar localization accuracy as CT-guided lung puncture, with shorter localization time and no complications. ENBDM is a safe and effective preoperative localization method for multiple ipsilateral pulmonary nodules.</p>","PeriodicalId":23271,"journal":{"name":"Translational lung cancer research","volume":"14 3","pages":"775-784"},"PeriodicalIF":4.0,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12000950/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144043090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Short-term peri- and intra-tumoral CT radiomics to predict immunotherapy response in advanced non-small cell lung cancer.","authors":"Ting Wang, Lei Chen, Xiao Bao, Zijuan Han, Zezhou Wang, Shengdong Nie, Yajia Gu, Jing Gong","doi":"10.21037/tlcr-24-973","DOIUrl":"https://doi.org/10.21037/tlcr-24-973","url":null,"abstract":"<p><strong>Background: </strong>Predicting response to immunotherapy is crucial for advanced non-small cell lung cancer (NSCLC) treatment planning, but effective predictive markers for immunotherapy efficacy are still lacking. This study aimed to develop an explainable machine learning model for predicting immunotherapy responses in advanced NSCLC patients.</p><p><strong>Methods: </strong>A total of 245 advanced NSCLC patients from two centers who received immunotherapy were retrospectively enrolled. For each primary tumor, three regions of interest were analyzed, namely, the intratumoral region (ITR), peritumoral region (PTR), and combined intratumoral and PTR (IPTR). Pre-radiomics features and delta-radiomics features reflecting the rate of change between radiomics features before and after treatment were extracted. Models for predicting immunotherapy responses were established via the extreme gradient boosting (XGBoost) classifier and assessed in terms of discrimination, calibration, and clinical utility. The SHapley Additive exPlanations (SHAP) tool was employed to explore the interpretability of the model. Kaplan-Meier (KM) analysis of progression-free survival (PFS) was conducted to evaluate the prognostic value of the prediction models.</p><p><strong>Results: </strong>The delta-radiomics models of ITR and IPTR demonstrated optimal performance in predicting immunotherapy response, significantly improving the area under the curve (AUC) to 0.85 and 0.83 in the internal validation cohort and 0.84 and 0.86 in the external validation cohort. SHAP revealed a strong relationship between the delta-radiomics feature values and the model-predicted probabilities. KM curves indicated that the high-risk groups identified by the delta-radiomics models had significantly worse PFS than did the low-risk groups across all cohorts.</p><p><strong>Conclusions: </strong>The results demonstrated that a model based on multiple time points outperformed one based on a single time point. The delta-radiomics model has been proved a noninvasive approach for assessing the response of advanced NSCLC patients to immunotherapy and facilitates individualized treatment decision making.</p>","PeriodicalId":23271,"journal":{"name":"Translational lung cancer research","volume":"14 3","pages":"785-797"},"PeriodicalIF":4.0,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12000948/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144001026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing the precision of auxiliary diagnosis for lung cancer through use of <i>SHOX2</i> and <i>RASSF1A</i> methylation status in lung biopsy and lymph node biopsy specimens.","authors":"Ping Gu, Yue Wang, Chunlei Shi, Yuqing Chen, Jialin Qian, Yanjie Niu, Hai Zhang, Yunxia Bao, Bin She, Xiaosha Ren, Iyare Izevbaye, Baohui Han, Hua Zhong, Yu Dong","doi":"10.21037/tlcr-2024-1082","DOIUrl":"https://doi.org/10.21037/tlcr-2024-1082","url":null,"abstract":"<p><strong>Background: </strong>Exfoliated cells in biopsy fluid are commonly utilized for cytological testing to complement histological examination. Nevertheless, the sensitivity of cytological testing is relatively low. Therefore, there is an urgent need to identify more sensitive biomarkers that can substitute for cytology and improve the overall diagnostic accuracy of lung cancer biopsies. The study aims to find biomarkers with greater sensitivity to replace cytology and enhance the overall diagnostic accuracy of lung cancer biopsies by evaluating the complementary roles of cytology and methylation in relation to histology.</p><p><strong>Methods: </strong>A cohort of 173 patients, including 127 individuals diagnosed with lung cancer and 46 individuals with benign lesions, was successively recruited from Shanghai Chest Hospital. These patients underwent cell smear, ThinPrep cytologic test (TCT), methylation analysis, and histological examination to assess the complementary roles of cytology and methylation in relation to histology could be evaluated.</p><p><strong>Results: </strong>The cutoff values of <i>SHOX2</i> and <i>RASSF1A</i>, as determined by the receiver operating characteristic (ROC) curve and scatter plot, were 9 and 12, respectively. The combination of <i>SHOX2</i> and <i>RASSF1A</i> (LungMe) yielded areas under the curve (AUCs) of 0.967 and 0.999 in lung biopsy and lymph node biopsy liquids, respectively. The sensitivity and specificity of LungMe were 95.3% (121/127) and 97.8% (45/46), respectively. The combination of cytology and histology in the diagnosis of lung cancer did not lead to an increase in diagnostic sensitivity or negative predictive value (NPV), while the combination of LungMe methylation and histology achieved a diagnostic sensitivity and NPV of 100%. The sensitivity of cytology was influenced by the biopsy method, but methylation effectively supplemented cytology in the diagnosis of lung cancer, with a combined diagnostic efficiency of 87.5% to 100%. Furthermore, positive methylation was identified in 87.5% of patients with negative cytology results from lung biopsy and in 100% of patients with negative cytology results in lymph node biopsy. Among samples tested as histologically negative, five cases were observed in which the methylation tests were positive. Among them, four cases were confirmed to be malignant after a second biopsy, surgery, or clinical follow-up, with one case determination pending further evaluation.</p><p><strong>Conclusions: </strong>The findings suggest that LungMe methylation could replace cytology as an adjunctive diagnostic tool for histology. Moreover, a positive methylation test result could indicate a potential malignancy, necessitating further confirmation by the hospital and thereby reducing the likelihood of missed diagnoses.</p>","PeriodicalId":23271,"journal":{"name":"Translational lung cancer research","volume":"14 3","pages":"897-911"},"PeriodicalIF":4.0,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12000937/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143998646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Will \"Sun\"-WUKONG, the monkey king, conquer EGFR exon 20 insertion mutation positive non-small cell lung cancer?","authors":"Molly Li, Ross A Soo","doi":"10.21037/tlcr-24-854","DOIUrl":"10.21037/tlcr-24-854","url":null,"abstract":"","PeriodicalId":23271,"journal":{"name":"Translational lung cancer research","volume":"14 2","pages":"323-327"},"PeriodicalIF":4.0,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11921394/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143670842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of metastasis and treatment patterns among different histopathologic types of lung cancer: analysis of 6 years of nationwide lung cancer cohort data in Korea.","authors":"Jeong Uk Lim, Kyu Yean Kim, Ho Cheol Kim, Tae-Jung Kim, Hong Kwan Kim, Mi Hyoung Moon, Kyongmin Sarah Beck, Yang Gun Suh, Chang Hoon Song, Jin Seok Ahn, Jeong Eun Lee, Jae Hyun Jeon, Chi Young Jung, Jeong Su Cho, Yoo Duk Choi, Seung Sik Hwang, Young Sik Park, Soon Ho Yoon, Joon Young Choi, Chang-Min Choi, Seung Hun Jang","doi":"10.21037/tlcr-24-770","DOIUrl":"10.21037/tlcr-24-770","url":null,"abstract":"<p><strong>Background: </strong>Personalized management of stage IV lung cancer requires a deeper understanding of metastatic patterns and the potential benefits of localized treatments for each histologic type. This study aims to identify patterns of both intrathoracic and extrathoracic metastases across various histologic types of lung cancer using a nationwide Korean lung cancer database.</p><p><strong>Methods: </strong>The study analyzed data from patients diagnosed with lung cancer between 2014 and 2019, sourced from the Korean Association of Lung Cancer Registry (KALC-R). Patients with stage IV lung cancer, indicated by M staging, were included to focus on metastatic patterns.</p><p><strong>Results: </strong>The cohort included 7,562 stage IV lung cancer patients, with adenocarcinoma being the most prevalent histologic type, comprising 49.22% of cases (3,722 patients). M stage categorization showed that 27.3% were M1a, 56.3% M1b, 15.7% M1c, and 0.6% unspecified. The adenosquamous type had the highest proportion of patients with metastases in three or more organs (42.9%). Metastases to the liver and bones were consistently associated with decreased survival across histologic types. In adenocarcinoma, strong associations were observed between extrathoracic metastatic sites, particularly between bone and liver [odds ratio (OR) =3.93] and liver and adrenal glands (OR =2.85). Multivariate analysis revealed that patients receiving radiotherapy to lung lesions had significantly better overall survival (OS) [hazard ratio (HR) =0.68; 95% confidence interval (CI): 0.60-0.78; P<0.001] compared to those who did not. Radiotherapy to extrathoracic metastases also significantly improved survival (HR =0.84; 95% CI: 0.77-0.93; P<0.001).</p><p><strong>Conclusions: </strong>Understanding metastasis patterns and treatment options specific to each lung cancer histologic type is essential for improving treatment strategies.</p>","PeriodicalId":23271,"journal":{"name":"Translational lung cancer research","volume":"14 2","pages":"363-384"},"PeriodicalIF":4.0,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11921192/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143670873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lung cancer organoids: a new strategy for precision medicine research.","authors":"Yuan Meng, Xinyi Shu, Jie Yang, Yangyueying Liang, Meiying Zhu, Xuerui Wang, Yue Li, Fanming Kong","doi":"10.21037/tlcr-24-921","DOIUrl":"10.21037/tlcr-24-921","url":null,"abstract":"<p><p>This article discusses new strategies for lung cancer organoids (LCOs) in precision medicine research. Precision medicine aims to identify and develop highly selective drugs targeted at specific disease markers for precise treatment. Given the genetic diversity among lung cancer cells, it is evident that different tumor cells may respond differently to various treatment regimens. LCOs can not only faithfully reproduce the pathological and genomic characteristics of samples, maintaining most variations, including driver gene mutations, but also preserve the cytological features of malignant tumor cells, showing a highly correlated in vitro drug screening response with the mutation spectrum in primary tumors. At this stage, several large-scale LCO biobanks have been established, providing ample sample resources for researchers. Based on this, the development of emerging technologies is expected to overcome limitations in the success rate, accuracy, and stability of the organoid culture process, significantly enhancing the level of precision medicine for lung cancer. This article mainly introduces the applications of LCO models in basic research, including the identification of drug targets, prediction of treatment efficacy, and overcoming drug resistance, assisting in the formulation of personalized treatment plans to improve treatment outcomes. Additionally, the article emphasizes the potential of cancer organoid co-culture models in the field of immunotherapy and their key role in advancing the evolution of precision medicine treatment strategies.</p>","PeriodicalId":23271,"journal":{"name":"Translational lung cancer research","volume":"14 2","pages":"575-590"},"PeriodicalIF":4.0,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11921219/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143671043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}